ArticleThe Lancet. Oncology2019
CD19-directed CAR T cells gain traction.
Article in The Lancet. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- CCR5 predicts neurotoxicity in CAR-T-cell therapy.British journal of haematology · 2025Article
- Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease.Molecular therapy. Methods & clinical development · 2024Article
- Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.American journal of hematology · 2021Review
- Targeted therapy of multiple myeloma.Exploration of targeted anti-tumor therapy · 2021Review
- Recent advances in CAR-T cell engineering.Journal of hematology & oncology · 2020Review
- A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?Advances in therapy · 2020Article
- T cell-engaging therapies - BiTEs and beyond.Nature reviews. Clinical oncology · 2020Review
- Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.JCI insight · 2020Article
- Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.Cancer biology & therapy · 2020Article
- State of the art in CAR T cell therapy for CD19+ B cell malignancies.The Journal of clinical investigation · 2020Review
- Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.Frontiers in immunology · 2020Article
- Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer.BioMed research international · 2020Article
- Recent updates on CAR T clinical trials for multiple myeloma.Molecular cancer · 2019Review
- Modelling CAR-T therapy in humanized mice.EBioMedicine · 2019Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30518503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.